
41-Year-Old Longevity Doctor Claims His Biological Age Is 24, Reveals 3 Supplements He Takes
A 41-year-old London-based primary care doctor has claimed his biological age is 24, thanks to his comprehensive routine and supplement regimen. According to tests taken 18 months ago, Dr. Mohammed Enayat's biological age was 17 years younger than his chronological age. He used GlycanAge and TruAge PACE tests, which measure inflammation and epigenetics, to determine his biological age.
Notably, Dr. Enayat, founder of Hum2n longevity clinic, has tracked his health for seven years using wearables like Oura ring and Whoop strap, along with regular blood, urine, and microbiome tests. Based on the results, he adjusts his longevity routine, including supplements. His core supplements include daily cycles of B complex, folate, magnesium, and omega-3 fatty acids.
"While I believe these supplements have supported my biological age reversal, I credit them as one component in a much broader framework," Mr Enayat told Business Insider.
1. Vitamin B complex
Dr. Enayat said he takes vitamin B complex and folate supplements due to a methylation gene defect that causes elevated homocysteine levels, increasing his risk of blood clots, heart attack, and stroke. The supplements help lower these levels. Generally, dietitians recommend obtaining nutrients through food and supplementing only when necessary, such as in cases of deficiency or inability to consume certain nutritious foods. Foods rich in B vitamins, like fish, poultry, legumes, and leafy greens, can also help reduce homocysteine levels.
Research suggests B vitamins may be linked to improved mood and dementia prevention, but further studies are required to confirm these findings.
"Even without a methylation-related gene defect, I would still consider taking a methylated B complex, particularly during periods of high stress, poor sleep, or intensive training, as these increase the demand for B vitamins," Mr Enayat said.
2. Magnesium
Dr. Enayat takes magnesium bisglycinate due to his naturally low magnesium levels from dietary intake. This form is chosen for its better absorption, helping to boost his levels. Magnesium is essential for bone health, blood sugar regulation, and muscle function, and can also be found in foods like legumes and leafy greens.
He reported that taking magnesium helps reduce muscle aches and improves his sleep, allowing him to fall asleep more easily.
3. Omega-3 Fatty Acids
Dr. Enayat takes a daily omega-3 supplement due to his naturally low levels. Omega-3s, found in oily fish, walnuts, and chia seeds, support heart health, reduce inflammation, and lower blood pressure. While eating fatty fish weekly is proven to protect against cardiovascular disease, the benefits of supplement form are less clear. However, some research suggests omega-3 supplements may have anti-ageing effects, with a recent study finding participants who took omega-3s daily had lower biological ages.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
an hour ago
- Time of India
Bharat Biotech in-licences GSK's Shigella vaccine
Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development Shigella vaccine candidate, altSonflex1-2-3. The vaccine candidate was being developed by GSK against Shigellosis, a severe form of bacterial diarrhoea that largely affects children aged below five years in low- and middle-income countries. While GSK has already conducted Phase I and II trials in Europe and Africa, Bharat Biotech will take up further development with Phase III clinical trials, regulatory advancement, and large-scale manufacturing, the Hyderabad-based vaccine maker said on Thursday. As part of the agreement, GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. The vaccine has been developed on the innovative generalised modules for membrane antigens (GMMA) based platform, which uses bacterial outer membranes to deliver the O Antigen to the immune system. "The in-licensed candidate, altSonflex1-2-3, already showed encouraging results in early-stage clinical trials. A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response," Bharat Biotech said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Toulouse: Nous recherchons des personnes pour tester les nouvelles aides auditives HearPro En savoir plus Undo "Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals," it added. Bharat Biotech Executive Chairman Dr Krishna Ella said: "With no approved vaccine currently available for Shigella and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment." He pointed out that Bharat Biotech already has a significant presence in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi. In 2021, GSK had inked a product transfer agreement for the world's first malaria vaccine, RTS,S, with Bharat Biotech. Follow more information on Air India plane crash in Ahmedabad here . Get real-time live updates on rescue operations and check full list of passengers onboard AI 171 .


Time of India
6 hours ago
- Time of India
Bharat Biotech in-licences GSK's Shigella vaccine candidate
HYDERABAD: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licenced pharma giant GSK's Shigella vaccine candidate -- altSonflex1-2-3. The vaccine candidate was being developed by GSK against Shigellosis, which is a severe form of bacterial diarrhoea that largely affects children aged five years and below in low- and middle-income countries. While GSK has already conducted Phase-I and II trials in Europe and Africa, Bharat Biotech will be taking up further development with Phase-III clinical trials, regulatory advancement and large-scale manufacturing, Bharat Biotech said on Thursday. As part of the agreement, GSK will continue its support to the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. The vaccine has been developed on the innovative generalized modules for membrane antigens (GMMA) based platform, which uses bacterial outer membranes to deliver the O Antigen to the immune system. 'The in-licensed candidate, altSonflex1-2-3, has already shown encouraging results in early-stage clinical trials. A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response,' the Hyderabad-based vaccine maker said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it better to shower in the morning or at night? Here's what a microbiologist says CNA Read More Undo 'Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals,' it added. Bharat Biotech executive chairman Dr Krishna Ella said: 'With no approved vaccine currently available for Shigella and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment.' He pointed out that the addition of this vaccine candidate to its portfolio will strengthen Bharat Biotech's already significant presence in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi. GSK already has an established relationship with BBIL, after it signed a product transfer agreement for the world's first malaria vaccine, RTS,S, to the Hyderabad-based company in 2021. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now


Hindustan Times
6 hours ago
- Hindustan Times
Neurotech and brain data: New frontier of privacy concerns
Consumer neurotechnology is no longer confined to sci-fi or academic labs. Thanks to AI advancements and shrinking chip sizes, devices that read brain activity, like EEG headsets, mood-tracking earbuds, and brain-controlled gaming accessories are entering the mainstream. Since 2011, over 130 startups have jumped into the consumer neurotech space. These tools, often embedded in wearables, promise productivity boosts, mental health insights, and immersive control over AR/VR environments. Tech giants like Apple and Snap are already exploring brain-computer interfaces (BCIs) for future headsets that could respond to mental states in real time. How Neurotech Works—And why It's risky EEG-based devices dominate this landscape, powering nearly 65% of consumer neurotech products. They track brainwave patterns linked to emotions, focus, and engagement levels. That may sound harmless until you realise this data could be mined to predict behaviours, preferences, or even political leanings. Imagine hyper-targeted ads based not on clicks, but on neural spikes. Or worse, cognitive surveillance, where employers or governments monitor attention levels, emotional stress, or signs of dissent. Cyberattacks targeting BCIs could introduce 'mental hacks', altering thought patterns or inducing confusion and distress. As one expert puts it, 'Brain data reveals thoughts before they're consciously expressed.' Regulatory gaps and urgent challenges The legal protections around all this? Alarmingly thin. While medical neurotech is regulated (MRIs or brain implants), consumer-grade EEG headsets fall into a grey zone. In the U.S., the FDA only monitors medical devices. State laws in places like California and Colorado require user consent for neural data use, but there's little enforcement. Internationally, concerns are mounting: China has tested neurotech in workplaces to track employee fatigue, while neuromarketing firms tap EEG feedback to fine-tune advertisements. 'Neural data could be weaponized for psychological warfare or blackmail.' Path forward So what now? We need clear federal laws that define how brain data can be collected, stored, and shared. Users should know exactly what's being tracked and who has access to it. Neural data must be encrypted, just like financial or medical records. Most importantly, the public must be made aware of what 'brain transparency' really means. Because the future of privacy may no longer be in your hands, but in your head. First Published Date: 12 Jun, 21:23 IST